Lord, Abbett & Co
STOK icon

Lord, Abbett & Co’s Stoke Therapeutics STOK Stock Holding History

Lord, Abbett & Co’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-126,303
Closed -$7.82M – 691
2020
Q4 		$7.82M Sell
126,303
-2,558
-2% -$117K 0.02% 566
2020
Q3 		$4.32M Sell
128,861
-3,867
-3% -$110K 0.01% 579
2020
Q2 		$3.16M Sell
132,728
-49,733
-27% -$1.18M 0.01% 601
2020
Q1 		$4.18M Buy
+182,461
New +$4.51M 0.02% 557

Other funds holding STOK

ALSV
ATP Life Science Ventures New York $898M AUM 84.86% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lord, Abbett & Co's STOK Position: Q1 2021 in Review

Lord, Abbett & Co sold out of Stoke Therapeutics (STOK) in Q1 2021, closing a stake of 126,303 shares — an estimated $7.82M sold.

Lord, Abbett & Co first reported a position in STOK in Q1 2020 and held it in 4 quarters. The position peaked at $7.82M in Q4 2020. 106 funds tracked by Wall St. Rank hold STOK as of Q1 2021.

  • Lord, Abbett & Co reported no remaining Stoke Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Lord, Abbett & Co sold 126,303 Stoke Therapeutics shares in Q1 2021, an estimated $7.82M.
  • Lord, Abbett & Co first reported a position in Stoke Therapeutics in Q1 2020 and held it in 4 quarters.
  • Lord, Abbett & Co's Stoke Therapeutics position peaked at $7.82M in Q4 2020.
  • 106 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2021.

Based on Lord, Abbett & Co's 13F filing for Q1 2021, filed 11 May 2021.